Roche Aktie [WKN: 851311 / ISIN: CH0012032113]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Roche Holding AG (Inhaberaktie)

11.10.24		FDA approves Roche’s Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation (Roche Holding AG)
11.10.24		FDA approves Roche’s Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation (GlobeNewswire)
10.10.24		Roche obtains CE certification for the first companion diagnostic to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOY (Roche Holding AG)
10.10.24		Roche obtains CE certification for the first companion diagnostic to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOY (GlobeNewswire)
26.09.24		Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis (GlobeNewswire)
26.09.24		Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis (Roche Holding AG)
24.09.24		Roche launches the first test to use its breakthrough TAGS technology for high throughput, simultaneous detection of 12 respiratory viruses (Roche Holding AG)
24.09.24		Roche launches the first test to use its breakthrough TAGS technology for high throughput, simultaneous detection of 12 respiratory viruses (GlobeNewswire)
23.09.24		WHO endorses dual-stain cytology (CINtec PLUS) testing in its cervical cancer prevention guidelines, advancing patient care and underlining Roche’s role in pioneering cervical cancer solutions (GlobeNewswire)
23.09.24		WHO endorses dual-stain cytology (CINtec PLUS) testing in its cervical cancer prevention guidelines, advancing patient care and underlining Roche’s role in pioneering cervical cancer solutions (Roche Holding AG)
19.09.24		Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses (Roche Holding AG)
19.09.24		Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses (GlobeNewswire)
16.09.24		FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis (GlobeNewswire)
16.09.24		FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis (Roche Holding AG)
13.09.24		FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy (GlobeNewswire)
13.09.24		FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy (Roche Holding AG)
10.09.24		Roche eröffnet Pharmaforschungs- und Entwicklungszentrum in Basel, um wissenschaftliche Innovationen zu beschleunigen (GlobeNewswire)
10.09.24		Roche opens Pharma Research and Development Center in Basel to accelerate scientific innovation (GlobeNewswire)
10.09.24		Roche opens Pharma Research and Development Center in Basel to accelerate scientific innovation (Roche Holding AG)
04.09.24		Roche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression for up to 48 weeks in patients with relapsing multiple sclerosis (GlobeNewswire)
04.09.24		Roche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression for up to 48 weeks in patients with relapsing multiple sclerosis (Roche Holding AG)
27.08.24		Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH (Roche Holding AG)
27.08.24		Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH (GlobeNewswire)
20.08.24		Roche responds to WHO’s declaration of a global health emergency due to the ongoing mpox outbreak (Roche Holding AG)
20.08.24		Roche responds to WHO’s declaration of a global health emergency due to the ongoing mpox outbreak (GlobeNewswire)
30.07.24		European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion (RVO) (Roche Holding AG)
30.07.24		European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion (RVO) (GlobeNewswire)
29.07.24		Roche closes acquisition of LumiraDx’s Point of Care technology to expand access to diagnostic testing in primary care (Roche Holding AG)
29.07.24		Roche closes acquisition of LumiraDx’s Point of Care technology to expand access to diagnostic testing in primary care (GlobeNewswire)
25.07.24		[Ad-hoc-Mitteilung gemäss Art. 53 KR] Verkäufe der Roche-Gruppe steigen im ersten Halbjahr 2024 um 5% (CER); starkes Wachstum im zweiten Quartal – Gewinnprognose für das Gesamtjahr erhöht (GlobeNewswire)
25.07.24		[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 5% (CER) in first half of 2024; strong growth in second quarter - full-year earnings outlook raised (Roche Holding AG)
25.07.24		[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 5% (CER) in first half of 2024; strong growth in second quarter – full-year earnings outlook raised (GlobeNewswire)
18.07.24		New data for Roche’s Susvimo demonstrates sustained efficacy in two serious diabetic eye conditions (Roche Holding AG)
18.07.24		New data for Roche’s Susvimo demonstrates sustained efficacy in two serious diabetic eye conditions (GlobeNewswire)
17.07.24		Roche’s Vabysmo showed extended durability, continued efficacy and a consistent safety profile in long-term diabetic macular edema (DME) study (Roche Holding AG)
17.07.24		Roche’s Vabysmo showed extended durability, continued efficacy and a consistent safety profile in long-term diabetic macular edema (DME) study (GlobeNewswire)
17.07.24		[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity (GlobeNewswire)
17.07.24		[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity (Roche Holding AG)
09.07.24		Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution offering critical predictions to people living with diabetes (GlobeNewswire)
09.07.24		Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution offering critical predictions to people living with diabetes (Roche Holding AG)
08.07.24		Roche to reintroduce Susvimo in the US for people with neovascular age-related macular degeneration (nAMD) (Roche Holding AG)
08.07.24		Roche to reintroduce Susvimo in the US for people with neovascular age-related macular degeneration (nAMD) (GlobeNewswire)
05.07.24		FDA approves Roche’s Vabysmo prefilled syringe (PFS) for three leading causes of vision loss (Roche Holding AG)
05.07.24		FDA approves Roche’s Vabysmo prefilled syringe (PFS) for three leading causes of vision loss (GlobeNewswire)
04.07.24		[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase II/III SKYSCRAPER-06 study in metastatic non-squamous non-small cell lung cancer (Roche Holding AG)
04.07.24		[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase II/III SKYSCRAPER-06 study in metastatic non-squamous non-small cell lung cancer (GlobeNewswire)
28.06.24		Roche’s Vabysmo gets CHMP recommendation for third indication retinal vein occlusion (RVO) (GlobeNewswire)
28.06.24		Roche’s Vabysmo gets CHMP recommendation for third indication retinal vein occlusion (RVO) (Roche Holding AG)
28.06.24		CHMP recommends EU approval of Roche’s PiaSky for people with PNH, a rare, life-threatening blood condition (GlobeNewswire)
28.06.24		CHMP recommends EU approval of Roche’s PiaSky for people with PNH, a rare, life-threatening blood condition (Roche Holding AG)

Zurück | 1 | 2 | Weiter

Newssuche

Roche Peer Group Nachrichten

16:00		Schwacher Wochentag in Frankfurt: TecDAX verbucht am Freitagnachmittag Abschläge
16:00		STOXX-Handel Euro STOXX 50 schwächelt nachmittags
16:00		XETRA-Handel: LUS-DAX notiert im Plus
16:00		Pluszeichen in Zürich: SPI legt am Freitagnachmittag zu
16:00		Handel in Europa: STOXX 50 schwächelt am Freitagnachmittag
16:00		Schwacher Handel in London: So bewegt sich der FTSE 100 am Freitagnachmittag

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	07.02.2025 16:43
Kaufwert:	EUR
	Hinzufügen Speichern

Roche Aktie [WKN: 851311 / ISIN: CH0012032113]

Nachrichten zu Roche Holding AG (Inhaberaktie)

Newssuche

Roche Peer Group Nachrichten

Meistgelesene Nachrichten